Xencor (NASDAQ:XNCR) Reaches New 12-Month Low – Here’s Why

Xencor, Inc. (NASDAQ:XNCR) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $12.69 and last traded at $12.89, with a volume of 723182 shares traded. The stock had previously closed at $12.87.

Analyst Ratings Changes

Several brokerages have recently weighed in on XNCR. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Wells Fargo & Company dropped their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.38.

Xencor Trading Down 2.8 %

The firm has a market capitalization of $889.23 million, a P/E ratio of -3.94 and a beta of 0.74. The business’s 50-day moving average is $16.92 and its 200 day moving average is $20.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. As a group, analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Xencor

A number of hedge funds have recently bought and sold shares of XNCR. Sterling Capital Management LLC grew its stake in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Xencor during the fourth quarter worth about $34,000. GAMMA Investing LLC grew its stake in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV grew its stake in Xencor by 63.5% during the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 1,213 shares in the last quarter. Finally, Quarry LP grew its stake in Xencor by 111.4% during the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 2,108 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.